PF-Atlas › Clinical Trials › NCT04926701

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

ETD001 single dose · Phase 1

Registry ID
NCT04926701
Phase
Phase 1
Status
Completed
Drug / intervention
ETD001 single dose
Sponsor
Enterprise Therapeutics Ltd
Start
2021-06-11
Enrollment
98
Locations
1

About this trial

This is a first in human study of ETD001 a new drug being developed for the treatment of cystic fibrosis. The study is a randomised, placebo-controlled, double-blind interventional study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of inhaled ETD001in healthy male and female subjects.

View NCT04926701 on ClinicalTrials.gov →

Explore related

All ETD001 single dose trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT04926701 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.